S&P 500
(0.80%) 5 277.51 points

Dow Jones
(1.51%) 38 686 points

Nasdaq
(-0.01%) 16 735 points

Oil
(-0.94%) $77.18

Gas
(0.35%) $2.58

Gold
(-0.79%) $2 347.70

Silver
(-3.10%) $30.56

Platinum
(0.63%) $1 044.50

USD/EUR
(-0.17%) $0.921

USD/NOK
(-0.49%) $10.49

USD/GBP
(-0.05%) $0.785

USD/RUB
(0.15%) $90.40

Realtime updates for Krystal Biotech Inc [KRYS]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

BUY

58.97%
return 72.14%

SELL

33.33%
return 26.86%

Last Updated31 May 2024 @ 16:00

25% discount on Stockinvest.us - Use code: Podcast

-0.96% $ 160.05

BUY 1010 min ago

@ $160.03

Issued: 31 May 2024 @ 12:06

Return: 0.01%

Previous signal: May 28 - 15:21

Previous signal: Sell

Return: 1.39 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.82% compare to its pairs and should correct upwards.

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States...

Stats
Today's Volume	171 362
Average Volume	316 585
Market Cap	4.57B
EPS	$0 ( 2024-05-13 )
Next earnings date	( $0.460 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	73.42
ATR14	$5.17 (3.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-20	Gangolli Julian S	Buy	20 000	Common Stock
2024-05-20	Gangolli Julian S	Sell	10 930	Common Stock
2024-05-20	Gangolli Julian S	Sell	7 090	Common Stock
2024-05-20	Gangolli Julian S	Sell	1 980	Common Stock
2024-05-20	Gangolli Julian S	Sell	20 000	Stock Option (Right to Buy)

INSIDER POWER
2.94
Last 100 transactions
Buy: 234 300 \| Sell: 216 670

Correlation (AI algo v.1.1b): Undervalued: 0.82% $161.14 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.67 (moderate negative)

Short: -0.75 (moderate negative)

Signal:(52) Neutral

Krystal Biotech Inc Correlation

10 Most Positive Correlations
TRVI	0.925
APLT	0.922
NNOX	0.915
KELYA	0.914
HOOD	0.91
BCYC	0.91
TSHA	0.905
ACVA	0.902
OSS	0.901
BTF	0.899

10 Most Negative Correlations
DBX	-0.941
SABR	-0.935
RAPT	-0.934
ROKU	-0.918
MFIN	-0.909
SSP	-0.881
FIVN	-0.869
AUPH	-0.865
CYAN	-0.863
GASS	-0.862

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Krystal Biotech Inc Correlation - Currency/Commodity

0.06
( neutral )

-0.07
( neutral )

0.00
( neutral )

0.62
( weak )

0.08
( neutral )

-0.82
( strong negative )

Krystal Biotech Inc Financials

Annual	2023
Revenue:	$50.70M
Gross Profit:	$42.60M (84.02 %)
EPS:	$0.400

FY	2023
Revenue:	$50.70M
Gross Profit:	$42.60M (84.02 %)
EPS:	$0.400

FY	2022
Revenue:	$0
Gross Profit:	$-4.05M (0.00 %)
EPS:	$-5.49

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.13

Financial Reports:

No articles found.

Krystal Biotech Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Krystal Biotech Inc

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.

Total Execution Time: 1.5825760364532 seconds
Number of API calls: 2
Number of DB calls: 8